Triple‑negative breast cancer (TNBC) accounts for 10‑15% of all breast cancer cases.
TNBCs lack estrogen and progesterone receptors and express low levels of HER2, and …

Aims: The purpose of this study was to explore the efficacy of immunotherapy for patients
with triple-negative breast cancer (TNBC). Materials & methods: Randomized clinical trials …

Triple-negative breast cancer (TNBC), a subtype of breast cancer, is defined as lacking
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor …

Background Several accomplishments have been achieved in triple-negative breast cancer
(TNBC) research over the last year. The phase III IMpassion130 trial comparing …

Breast cancer is the most commonly diagnosed cancer in women and is one of the leading
causes of death from cancer in women worldwide. Despite the significant benefits of using …

Triple-negative breast cancer (TNBC) is a heterogeneous subtype of breast cancer that is
often associated with an aggressive phenotype and a poor prognosis. Cytotoxic …

Triple-negative breast cancer (TNBC) has a worse prognosis and remains the most
challenging breast cancer subtype to treat. This is largely related to the heterogeneity of this …

Abstract Triple Negative Breast Cancer (TNBC) is a highly heterogeneous subtype of breast
cancer that lacks the expression of oestrogen receptors, progesterone receptors and human …

Simple Summary The breakthrough of immunotherapy in melanoma has generated a
glimmer of hope for lethal triple negative breast cancer (TNBC). This review summarizes the …

Numerous malignancies, including metastatic triple-negative breast cancer (TNBC), which
has long been associated with a poor prognosis, have been transformed by the widespread …